Logo-bma
Biomed adv. 2025;2(3): 131-136. doi: 10.34172/bma.26

Review Article

New developments in epigenetic and genetic biomarkers for differentiated thyroid cancer (DTC): Moving toward accurate diagnosis and treatment by 2025

Samaneh Hosseinzadeh ORCID, Safura Pakizehkar, Hoda Golab-Ghadaksaz, Laleh Hoghooghi Rad, Mehdi Hedayati * ORCID

Cited by CrossRef: 0

1- Naeem M, Wu N, Wu Y, Nawaz S, Jing R, Luo Y, Yi S. Integrated transcriptomics approach identifies the upregulated SLC7A5, and associated pathways across different thyroid cancer cell types. Front Genet. 2026;17 [Crossref]

Acceptance Rate: 35%
Submission to First Decision: 20 Days
Received to Acceptance: 60 Days
Acceptance to Publication: 40 Days
*Average article statistics from the last 12 months of data.

In collaboration with